Form 4: Paragon 28 Director Schnettler Reports Share Disposal Following Merger with Zimmer Biomet

Thomas Schnettler, a director at Paragon 28, reports the disposal of common stock due to the merger with Zimmer Biomet, receiving cash and contingent value rights.

Summary

• Thomas Schnettler, a director of Paragon 28, filed a Form 4 detailing changes in beneficial ownership.
• The filing is related to the merger between Paragon 28 and Zimmer Biomet Holdings, Inc.
• As a result of the merger, each share of Paragon 28 common stock was converted into the right to receive $13.00 in cash and one contingent value right (CVR) potentially worth up to $1.00.
• Schnettler disposed of 45,035 shares of common stock as a result of the merger.
• Restricted stock units with time-based vesting also vested and were canceled, with holders receiving cash and CVRs for each share.
• The merger was completed on April 21, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides immediate cash value to shareholders, with the potential for additional value through the CVR. However, the CVR's value is contingent on future performance.

Positives

• Shareholders received $13.00 in cash per share as part of the merger.
• Shareholders also received a Contingent Value Right (CVR) with a potential value of up to $1.00 per share.
• Restricted stock units vested, providing additional value to holders.

Risks

• The contingent payment of up to $1.00 per share is dependent on the achievement of specified milestones, introducing uncertainty.

Future Outlook

The future value depends on the achievement of milestones specified in the CVR agreement.

Industry Context

This merger reflects ongoing consolidation trends in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• Mergers in the medical device industry often involve a combination of upfront cash payments and contingent value rights (CVRs).
• CVRs are used to bridge valuation gaps and align the interests of the acquiring and acquired companies.
• Similar deals include Johnson & Johnson's acquisition of Actelion, which also involved CVRs tied to specific milestones.
• The $13.00 cash consideration is within the typical range for acquisitions of companies of Paragon 28's size and profile.

Stakeholder Impact

• Shareholders receive cash and potential future value through CVRs.
• Employees may experience changes as the company integrates with Zimmer Biomet.
• Customers may benefit from the combined product offerings of the two companies.

Next Steps

• Shareholders will need to monitor the progress of the milestones outlined in the CVR agreement to determine the potential value of the CVRs.
• Zimmer Biomet will integrate Paragon 28's operations and products into its existing business.

Key Dates

Keywords

Merger, Paragon 28, Zimmer Biomet, Form 4, Beneficial Ownership, Schnettler, Contingent Value Right, CVR